[go: up one dir, main page]

EP1626969A1 - Composes heterocycliques - Google Patents

Composes heterocycliques

Info

Publication number
EP1626969A1
EP1626969A1 EP04731345A EP04731345A EP1626969A1 EP 1626969 A1 EP1626969 A1 EP 1626969A1 EP 04731345 A EP04731345 A EP 04731345A EP 04731345 A EP04731345 A EP 04731345A EP 1626969 A1 EP1626969 A1 EP 1626969A1
Authority
EP
European Patent Office
Prior art keywords
amino
alkylamino
alkyl
alkoxy
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04731345A
Other languages
German (de)
English (en)
Inventor
Christoph Gerdes
Elisabeth Perzborn
Jens Pohlmann
Susanne Röhrig
Alexander Straub
Christian R. Thomas
Arounarith Tuch
Karl-Heinz Schlemmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1626969A1 publication Critical patent/EP1626969A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to the field of blood coagulation.
  • the invention relates in particular to certain heterocyclic compounds, processes for their preparation, their use for the treatment and / or prophylaxis of diseases and their use for the production of medicaments for the treatment and / or prophylaxis of diseases.
  • Blood coagulation is a protective mechanism of the organism, with the help of which defects in the vascular wall can be "sealed" quickly and reliably. In this way, blood loss can be avoided or minimized.
  • Hemostasis after vascular injury occurs essentially through the coagulation system, in which an enzymatic cascade occurs
  • Complex reactions are triggered by plasma proteins, involving numerous blood coagulation factors, each of which, when activated, converts the next inactive precursor into its active form, and at the end of the cascade there is the conversion of the soluble fibrinogen to the insoluble fibrin, so that it is Traditionally, a distinction is made in blood coagulation between the intrinsic and extrinsic systems, which lead to a final common reaction pathway, in which factor Xa, which is formed from the proenzyme factor X, plays a key role, since it combines both clotting pathways
  • the activated serine protease Xa cleaves prothrombin to thrombin.
  • thrombin in turn in turn cleaves fibrinogen to fibrin. Subsequent cross-linking of the fibrin monomers leads to the formation of blood clots and thus hemostasis.
  • thrombin is a potent trigger for platelet aggregation, which also makes a significant contribution to hemostasis.
  • Hemostasis is subject to a complex regulatory mechanism.
  • An uncontrolled activation of the coagulation system or a defective inhibition of the activation processes can cause local thrombosis or embolism to form in vessels (arteries, veins, lymphatic vessels) or cardiac cavities. This can lead to serious thromboembolic disorders.
  • hypercoagulability - systemically - can lead to disseminated intravascular coagulation in case of consumption coagulopathy.
  • Thromboembolic complications also occur in microangiopathic hemolytic anemia, extracorporeal blood circulation, such as hemodialysis, and heart valve prostheses.
  • Thromboembolic disorders are the leading cause of morbidity and mortality in most industrialized countries (Heart Disease; A Textbook of Cardiovascular Medicine, Eugene Braunwald, 5th Edition, 1997, WB Saunders Company, Philadelphia; Rheine und special pharmacology and toxicology, W. Forth, D.Henschler, W. Rummel, K. Starke, 7th edition, 1996, Spektrum Akademischer Verlag Heidelberg).
  • heparin is used for the therapy and prophylaxis of thromboembolic diseases, which is administered parenterally or subcutaneously. Because of the more favorable pharmacokinetic properties, low molecular weight heparin is increasingly preferred today; however, this also does not prevent the known disadvantages described below, which exist in the treatment with heparin. For example, heparin is orally ineffective and has a comparatively short half-life. Because heparin inhibits several factors in the blood coagulation cascade at the same time, it has an unselective effect.
  • the vitamin K antagonists represent a second class of anticoagulants. These include, for example, 1,3-indanediones, but above all compounds such as warfarin, phenprocoumon,
  • Dicumarol and other coumarin derivatives that unselectively inhibit the synthesis of various products of certain vitamin K-dependent coagulation factors in the liver.
  • factor Xa represents one of the most important targets for anticoagulant active substances [SAV Raghavan, M. Dikshit, Drugs of the Future 2002, 27, 669-683 "Recent advances in the Status and targets of antithrombotic agents "; HA Wieland, V. Laux, D. Kozian, M. Lorenz, Current Opinion in Investigational Drugs 2003, 4, 264-271" Approaches in anticoagulation: Rationales for target positioning "].
  • the object of the present invention is now to provide new substances for combating diseases which have a wide therapeutic range.
  • the present invention relates to compounds of the formula (I)
  • R 5 represents hydrogen or alkyl
  • M represents an aryl, pyridyl, pyrimidyl, pyridazinyl, thienyl, furyl or pyrrolyl radical which is unsubstituted or mono- or disubstituted with radicals independently selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, carbamoyl, Hydroxy, amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl optionally substituted by alkylamino, alkylcarbonyloxy, alkyl, alkylamino and alkoxy,
  • Alkyl, alkylamino and alkoxy can in turn be substituted by amino, hydroxy, alkylamino, alkoxy, heterocyclyl or heterocyclylcarbonyl,
  • R 1 represents an aryl, heteroaryl or heterocyclyl radical which is unsubstituted or mono-, di- or trisubstituted by radicals independently selected from the group consisting of halogen, optionally alkyl-substituted by amino, amino, alkyl- amino, hydroxy, alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, oxo, carboxyl and cyano,
  • R 6 , R 8 , R 11 , R 13 and R 15 independently of one another, denote hydrogen, alkyl or cycloalkyl
  • Alkyl and cycloalkyl can in turn be substituted by amino, hydroxy, alkylamino or alkoxy,
  • R 7 , R 9 , R 12 , R 14 and R 16 independently of one another, denote alkyl or cycloalkyl
  • Alkyl and cycloalkyl can in turn be substituted by amino, hydroxy, alkylamino or alkoxy,
  • R 6 and R 7 together with the NC (O) group to which they are attached, form a 4- to 7-membered heterocycle which may also contain one or two double bonds,
  • R 8 and R 9 together with the NC (O) -N (R 10 ) group to which they are attached, form a 5- to 7-membered heterocycle
  • R 10 is hydrogen, amino, hydroxy, alkylcarbonyl, alkylcarbonyloxy, alkoxycarbonyl,
  • Alkyl, alkylamino and alkoxy can in turn be substituted by amino, hydroxy, alkylamino, cycloalkylamino, alkoxy or heterocyclyl,
  • R 11 and R 12 together with the NS (O) x group to which they are attached, form a 4- to 7-membered heterocycle which may also contain one or two double bonds,
  • R 13 and R 14 together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycle
  • R 15 and R 16 together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycle
  • Alkyl, alkylamino and alkoxy can in turn be substituted by amino, hydroxy, alkylamino, alkoxy or heterocyclyl,
  • x means 1 or 2
  • y means 0 or 1
  • R 3 represents hydrogen or alkyl
  • R 4 denotes hydrogen, alkoxycarbonyl, alkylaminocarbonyl or alkyl
  • Alkyl in turn can be substituted by hydroxy, amino, alkoxy or alkylamino,
  • Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts; the compounds of the formula (I) encompassed by the formulas mentioned below and their salts, solvates and solvates of the salts, and the compounds encompassed by the formula (I) hereinafter referred to as exemplary embodiments and their salts, solvates and solvates of the salts, insofar as the Compounds of formula (I) mentioned below are not already salts, solvates and solvates of the salts.
  • the compounds according to the invention can exist in stereoisomeric forms (enantiomers, diastereomers).
  • the invention therefore encompasses the enantiomers or diastereomers and their respective mixtures.
  • the stereoisomerically uniform constituents can be isolated in a known manner from such mixtures of enantiomers and / or diastereomers.
  • the present invention encompasses all tautomeric forms.
  • preferred salts are physiologically acceptable salts of the compounds according to the invention.
  • Physiologically acceptable salts of the compounds of the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid acetic acid, trifluoroacetic acid, propionic acid
  • Physiologically acceptable salts of the compounds according to the invention also include salts of conventional bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines with 1 to 16 C - Atoms such as, by way of example and by way of preference, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclo-hexylamine, dimethylarninoethanol, procaine, dibenzylamine, N-methylmorpholine, dihydroabietylamine, arginylendiamin and lysidine, lysidine.
  • alkali metal salts for example sodium and potassium salts
  • alkaline earth metal salts for example calcium and magnesium salts
  • solvates are those forms of the compounds which, in the solid or liquid state, form a complex by coordination with solvent molecules form. Hydrates are a special form of solvate, in which coordination takes place with water. Hydrates are preferred as solvates in the context of the present invention.
  • Alkoxy is exemplary and preferably methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
  • Alkylcarbonyl is exemplary and preferably acetyl, propanoyl and tert-butanoyl.
  • Alkylamino stands for an alkylamino radical with one or two (independently selected) alkyl substituents, for example and preferably for methylamino, ethylamino, n-propylamino, isopropylamino, tert.-butylamino, n-pentylamino, n-hexylamino, N, N-dimethylamino, NN -Diethylamino, N-ethyl-N-methylamino, N-methyl-Nn-propylamino, N-isopropyl-Nn-propylamino, N-tert-butyl-N-methylamino, N-ethyl-Nn-pentylamino and / Vn hexyl-N-meftylamino.
  • Alkylaminocarbonyl stands for an alkylaminocarbonyl radical with one or two (independently selected) alkyl substituents, by way of example and preferably for methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, tert.-butylaminocarbonyl, n-pentylaminocarbonyl, n-hexylaminocarbonyl, N-hexylaminocarbonyl , N, N-diethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, N-methyl-Nn-propylaminocarbonyl, N-isopropyl-Nn-propylaminocarbonyl, N-tert-butyl-N-methylaminocarbonyl, N-ethyl-Nn- pentylamino-carbonyl and Nn-hexy
  • Alkylaminosulfonyl stands for an alkylaminosulfonyl radical with one or two (independently selected) alkyl substituents, by way of example and preferably for methylaminosulfonyl, ethylaminosulfonyl, n-propylaminosulfonyl, isopropylaminosulfonyl, tert.-butylaminosulfonyl, n-pentylaminosulfonyl, n-hexyl-nylylamino, N, N-diethylaminosulfonyl, N-ethyl-N-methylaminosulfonyl, N-methyl-Nn-propylaminosulfonyl, N-isopropyl-Nn-propylaminosulfonyl, N-tert-butyl-N-methylaminosulfonyl, N-ethyl-Nn -pentyl
  • Alkylsulfonyl represents a straight-chain or branched alkylsulfonyl radical. Examples and preferably mentioned are: methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, tert-butylsulfonyl, n-pentylsulfonyl and n-hexylsulfonyl.
  • Alkoxycarbonyl is exemplified and preferably methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxycarbonyl.
  • Alkylcarbonyloxy is exemplary and preferably acetoxy and propionyloxy.
  • Cycloalkyl per se and in cycloalkylamino stands for a cycloalkyl group with generally 3 to 8, preferably 5 to 7 carbon atoms, by way of example and preferably for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Cycloalkylamino stands for a cycloalkylamino radical with one or two (independently selected) cycloalkyl substituents, by way of example and preferably for cyclopropylamino, cyclobutyla ino, cyclopentylamino, cyclohexylamino and cycloheptyla ino.
  • Aryl stands for a mono-, bi- or tricyclic aromatic, carbocyclic radical with usually 6 to 14 carbon atoms; exemplary and preferably for phenyl, naphthyl and phenanthrenyl, in particular for phenyl and naphthyl.
  • Heteroaryl stands for an aromatic, mono- or bicyclic radical with generally 5 to 10, preferably 5 to 6 ring atoms and up to 4, preferably up to 2 heteroatoms from the series S, O and N, by way of example and preferably for thienyl, furyl , Pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl.
  • Heterocyclyl per se and in heterocyclylcarbonyl stands for a mono- or polycyclic, preferably mono- or bicyclic, optionally benzo-fused, non-aromatic heterocyclic radical with usually 4 to 7, preferably 5 to 7 ring atoms and up to 3, preferably up to 2 Heteroatoms and / or hetero groups from the series N, O, S, SO, SO 2 .
  • the heterocyclyl residues can be saturated or partially unsaturated.
  • 5- to 7-membered, monocyclic saturated heterocyclyl radicals having up to two heteroatoms from the O, N and S series are preferred, such as, for example and preferably, tetrahydrofuranyl, pyrrolidinyl, pyrrolinyl, piperidinyl, piperazinyl, morpholinyl.
  • Heterocyclylcarbonyl is exemplary and preferably tetrahydrofuran carbonyl, pyrrolidine carbonyl, pyrroline carbonyl, piperidinecarbonyl, piperazinecarbonyl, morpholinecarbonyl.
  • Halogen stands for fluorine, chlorine, bromine and iodine.
  • radicals in the compounds according to the invention are substituted, the radicals, unless otherwise specified, can be mono- or polysubstituted.
  • the meaning of all radicals which occur more than once is independent of one another. A substitution with one, two or three identical or different substituents is preferred. Substitution with a substituent is very particularly preferred.
  • R 5 represents hydrogen or methyl
  • M represents a phenyl or pyridyl radical which is optionally simply substituted by fluorine, chlorine, trifluoromethyl, cyano, nitro, hydroxyl, amino, acetyl, alkyl, alkylamino or alkoxy,
  • Alkyl, alkylamino and alkoxy can in turn be substituted by amino, hydroxy, alkylamino, alkoxy or heterocyclyl
  • R 1 represents a radical phenyl, pyridyl, thienyl, furyl or pyrrolyl which is unsubstituted or mono- or disubstituted with radicals, independently selected from the group of fluorine, chlorine, bromine, methyl, ethyl, aminomethyl, aminoethyl,
  • R 2 represents a phenyl or pyridyl radical
  • R 6 , R 7 , R 8 , R 9 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 independently of one another, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec Butyl, isobutyl, tert-butyl, cyclopropyl or cyclopentyl,
  • R 6 and R 7 together with the NC (O) group to which they are attached, form a 5- or 6-membered heterocycle which may also contain one or two double bonds,
  • R 8 and R 9 together with the NC (O) -N (R 10 ) group to which they are attached, form a 5- or 6-membered heterocycle
  • R 10 denotes hydrogen or alkyl
  • Alkyl in turn can be substituted by amino, hydroxy, alkylamino, cycloalkylamino, alkoxy or 5- or 6-membered heterocyclyl, R 11 and R 12 , together with the NS (O) x group to which they are attached, form a 5- or 6-membered heterocycle which may also contain one or two double bonds,
  • R 13 and R 14 together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocycle
  • R 15 and R 16 together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycle
  • R 6 and R 7 ; R 8 and R 9 ; R 11 and R 12 ; R 13 and R 14 or heterocycle formed by R 15 and R 16 optionally contains a further heteroatom from the series N, O and / or S and is unsubstituted or mono- or disubstituted with radicals independently selected from the group of amino , Hydroxy, oxo, acetyl, alkoxycarbonyl, alkylaminocarbonyl, alkyl, alkylamino and alkoxy,
  • Alkylamino, alkoxy or 5- or 6-membered heterocyclyl can be substituted
  • R 3 represents hydrogen
  • R 4 represents hydrogen or alkyl
  • Alkyl in turn can be substituted by hydroxy, amino, alkoxy or alkylamino,
  • M denotes phenyl, which is optionally simply substituted by fluorine, chlorine, trifluoromethyl, cyano, amino, methyl, ethyl, methylamino or dimethylamino,
  • Methyl and ethyl can in turn be substituted by amino, hydroxy, methylamino, dimethylamino, methoxy, morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl,
  • R 1 means thienyl which is simply substituted by chlorine, bromine or methyl
  • R 2 is a residue
  • this radical is unsubstituted or is mono- or disubstituted with radicals independently selected from the group of amino, hydroxy, methoxy, methylamino and dimethylamino, * stands for the connection point to M,
  • R 10 denotes hydrogen, methyl, ethyl or n-propyl
  • Cyclopropylamino, isopropylamino, tert-butylamino, dimethylamino, diethylamino, methoxy, ethoxy, morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl can be substituted,
  • R 3 represents hydrogen
  • R 4 represents hydrogen
  • radical definitions specified in detail in the respective combinations or preferred combinations of radicals are replaced as desired by radical definitions of another combination, irrespective of the respectively specified combinations of the radicals.
  • the invention further relates to a process for the preparation of the compounds according to the invention, which is characterized in that either
  • R 1 and Y have the meanings given above and
  • X 1 represents chlorine or hydroxy
  • V represents alkoxy or chlorine
  • X 2 represents a leaving group, for example chlorine
  • R 3 and R 4 have the meanings given above,
  • a * means [N] -C (O) -CH 2 - * [C]
  • Compounds of the formula (TV) can be obtained, for example, from compounds of the formula (VIH) by reaction with compounds of the formula (XVI) embedded image in which
  • R 1 , R 3 , R 4 and Y have the meanings given above,
  • Process step (II) + (IH) -> (I) is preferably carried out in an inert solvent, preferably tetrahydrofuran or dimethylformamide, optionally in the presence of auxiliaries and / or bases in a temperature range from 0 ° C to the reflux temperature, preferably in the range from 0 ° C to room temperature.
  • an inert solvent preferably tetrahydrofuran or dimethylformamide
  • Trialkylamines e.g. Triethylamine, N-methylmorpholine (NMM), N-methylpiperidine, N, N-diisopropylethylamine (Hunig base) or 4-N, N-dimethylaminopyridine (DMAP) or pyridine.
  • NMM N-methylmorpholine
  • DMAP N-dimethylaminopyridine
  • Process step (TV) + (V) -> (I) is preferably carried out with ethyl chloroacetate or chloroacetyl chloride as (V) in the presence of a base, preferably sodium hydride or potassium tert-butoxide, in an inert solvent, preferably tetrahydrofuran or dimethylformamide, at room temperature ,
  • a base preferably sodium hydride or potassium tert-butoxide
  • an inert solvent preferably tetrahydrofuran or dimethylformamide
  • Process steps (IV) + SOCl 2 ->(I); (VI) + SOCl 2 ->(I); (XHI) + SOCl 2 ->(VU); (XV) + SOCl 2 -> (VE) are preferably carried out in the presence of N, N-diisopropylethylamine (Hunig base) as the base, in tetrahydrofuran as the solvent in a temperature range from -78 ° C to room temperature.
  • Process steps (IV) + SOCl 2 + "Ox"->(I); (VI) + SOCl 2 + “Ox”->(I); (XIU) + SOCl 2 + "Ox"->(VU); (XV) + SOCl 2 + "Ox”-> (VU) are preferably carried out in the first step by reaction with thionyl chloride in the presence of N, N-diisopropylethylamine (Hunig base) as the base, in tetrahydrofuran as the solvent in a temperature range of -78 ° C to room temperature.
  • the subsequent oxidation is preferably carried out with sodium periodate in the presence of ruthenium (i ⁇ ) chloride hydrate in acetonitrile in a temperature range from 0 ° C. to room temperature.
  • the cyclization reactions to cyclic urea derivatives in process steps (VI) -> (I) and (XV) -> (VU.) are preferably carried out using carbonyldiimidazole (CDI) as carbonic acid. equivalent in the presence of 4-N, N-dimethylaminopyridine (DMAP) as a base in tetrahydrofuran as a solvent in a temperature range from room temperature to 80 ° C.
  • CDI carbonyldiimidazole
  • DMAP 4-N, N-dimethylaminopyridine
  • the cyclization reaction to oxazolidine ions in process step (IV) -> (I) and to imidazolidine ions in process step (VI) -> (I) is preferably carried out with N, N'-thiocarbonyldiimidazole in the presence of 4-N, N-dimethylaminopyridine (DMAP) as a base in dimethylformamide or tetrahydrofuran as a solvent in a temperature range from room temperature to 80 ° C.
  • DMAP N-dimethylaminopyridine
  • the phthalimide protective group in process step (VU) -> (U) is preferably cleaved using hydrazine hydrate or methylamine in methanol or ethanol as solvent in a temperature range from room temperature to 80 ° C.
  • Process step (VUI) + (IX) -> (X) is preferably carried out in aqueous solution under reflux.
  • the conversion of the carboxyl group to the corresponding alcohol in process step (X) -> (XI) is preferably carried out via the stage of the corresponding methyl ester by reacting (X) with thionyl chloride in methanol at 0 ° C. and then reducing the resulting methyl ester with sodium borohydride in methanol Reflux to (XI).
  • Process step (XI) -> (VU) is preferably carried out by reacting (XI) with phthalimide in the presence of triphenylphosphine and azodicarboxylates such as diethyl azodicarboxylate (DEAD) in tetrahydrofuran in a temperature range from 0 ° C. to room temperature ,
  • Process steps (VUI) + (XU) -> (XHI) and (VIII) + (XVI) -> (IV) are preferably carried out with primary amine or aniline derivatives in 1,4-dioxane, 1,4-dioxane Water mixtures, ethanol or ethanol-water mixtures in a temperature range from room temperature to 80 ° C or alternatively in the presence of catalytic amounts of ytterbium (IIT) trifluoromethanesulfonate in tetrahydrofuran in a temperature range from room temperature to 80 ° C.
  • IIT ytterbium
  • the oxidation of the alcohol function to the corresponding ketone in process steps (XIJT) -> (XIV) and (IV) -> (XVII) is preferably carried out under the conditions of Swera oxidation with dimethyl sulfoxide and oxalyl chloride or similar methods based on activated DMSO, such as for example with dimethyl sulfoxide and trifluoroacetic anhydride or dimethyl sulfoxide and N, N'-dicyclohexylcarbodiimide / phosphoric acid (Pfitzner-Moffat oxidation).
  • the reductive amination of the keto function in process steps (XTV) -> (XV) and (XVU) -> (VI) is preferably carried out using sodium cyanoborohydride as reducing agent in the presence of acetic acid and molecular sieve (4A) in methanol.
  • the compounds according to the invention show an unforeseeable, valuable pharmacological spectrum of action.
  • the compounds according to the invention are selective inhibitors of the blood coagulation factor Xa, which act in particular as anticoagulants.
  • the present invention furthermore relates to the use of the compounds according to the invention for the treatment and / or prophylaxis of diseases, preferably thromboembolic diseases and / or thromboembolic complications.
  • the “thromboembolic diseases” include, in particular, diseases such as a heart attack with an ST segment increase (STEMI) and without an ST segment increase (non-STEMI), stable angina pectoris, unstable angina pectoris, reocclusions and Restenosis after coronary interventions such as angioplasty or aortocoronary bypass, thrombotic and thromboembolic stroke, transient ischemic attacks, peripheral arterial disease, pulmonary embolism, deep venous thrombosis and renal venous thrombosis.
  • diseases such as a heart attack with an ST segment increase (STEMI) and without an ST segment increase (non-STEMI)
  • stable angina pectoris such as a heart attack with an ST segment increase (STEMI) and without an ST segment increase (non-STEMI)
  • stable angina pectoris such as a heart attack with an ST segment increase (STEMI) and without an ST segment increase (non-STEMI)
  • unstable angina pectoris such as CAD or
  • the compounds according to the invention are suitable for the treatment of disseminated intravascular coagulation (DIC).
  • DIC disseminated intravascular coagulation
  • Thromboembolic complications also occur in microangiopathic hemolytic anemia, extracorporeal blood circulation, such as hemodialysis, and heart valve prostheses.
  • the compounds according to the invention are also suitable for the prophylaxis and / or treatment of atherosclerotic vascular diseases and inflammatory diseases such as rheumatic diseases of the musculoskeletal system, and also for the prophylaxis and / or treatment of Alzheimer's disease and neoplastic diseases such as cancer.
  • the compounds according to the invention can also be used to prevent coagulation ex vivo, for example in the case of blood samples or biological samples which contain factor Xa.
  • the present invention furthermore relates to the use of the compounds according to the invention for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
  • the present invention furthermore relates to the use of the compounds according to the invention for the manufacture of a medicament for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is a method for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases, using an anticoagulant effective amount of the compound according to the invention.
  • the present invention furthermore relates to a method for preventing blood coagulation in vitro, in particular in the case of preserved blood or biological samples which contain factor Xa, which is characterized in that an anticoagulant effective amount of the compound according to the invention is added.
  • the present invention furthermore relates to medicaments containing a compound according to the invention and one or more further active compounds, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
  • suitable combination active ingredients which may be mentioned are:
  • Lipid-lowering agents in particular HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors,
  • Coronary therapeutic agents / vasodilators in particular ACE (angiotensin converting enzyme) inhibitors; AII (angiotensin H.) Receptor antagonists; ⁇ -adrenoceptor antagonists; alpha-1-adrenoceptor antagonists; diuretics; Calcium channel blockers; Substances which cause an increase in cyclic guanosine monophosphate (cGMP), for example stimulators of soluble guanylate cyclase;
  • Plasminogen activators thrombolytics / fibrinolytics
  • compounds that increase thrombolysis / fibrinolysis such as inhibitors of the plasminogen activator inhibitor (PAI inhibitor) or inhibitors of the thrombin-activated fibrinolysis inhibitor (TAFT);
  • anticoagulant substances anticoagulants
  • anti-platelet substances platelet inhibitors, thrombocyte aggregation inhibitors
  • Fibrinogen receptor antagonists (glycoprotein Hb / ⁇ ia antagonists).
  • the present invention furthermore relates to medicaments which contain a compound according to the invention, usually together with one or more pharmacologically acceptable auxiliaries, and to their use for the purposes mentioned above.
  • connection according to the invention can act systemically and / or locally.
  • it can be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic or as an implant or stent.
  • the compound according to the invention can be administered in suitable application forms for these application routes.
  • state-of-the-art, fast and / or modified application forms which release the compound according to the invention and which contain the compound according to the invention in crystalline and / or amorphized and / or dissolved form, such as e.g. Tablets (non-coated or coated tablets, for example with gastric juice-resistant, delayed dissolving or insoluble coatings which control the release of the compound according to the invention), rapidly disintegrating tablets or films / wafers in the oral cavity, capsules, dragees, granules, pellets, powder, emulsions, Suspensions or solutions.
  • Tablets non-coated or coated tablets, for example with gastric juice-resistant, delayed dissolving or insoluble coatings which control the release of the compound according to the invention
  • rapidly disintegrating tablets or films / wafers in the oral cavity capsules, dragees, granules, pellets, powder, emulsions, Suspensions or solutions.
  • Parenteral administration can be done by bypassing a resorption step (e.g. intravenously, intraarterially, intracardially, intraspinally or intralumbally) or by switching on absorption (e.g. intramuscularly, subcutaneously, intracutaneously or intraperitoneally).
  • a resorption step e.g. intravenously, intraarterially, intracardially, intraspinally or intralumbally
  • absorption e.g. intramuscularly, subcutaneously, intracutaneously or intraperitoneally.
  • Suitable forms of application for parenteral administration include injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • inhalation pharmaceutical forms including powder inhalers, nebulizers
  • nasal drops, solutions, sprays are suitable
  • the compound according to the invention can be converted into the administration forms mentioned in a manner known per se. This is done using inert, non-toxic, pharmaceutically suitable excipients.
  • Carriers e.g. microcrystalline cellulose, lactose, mannitol etc.
  • solvents e.g. liquid polyethylene glycols
  • emulsifiers and dispersing or wetting agents e.g. sodium dodecyl sulfate, polyoxysorbitanoleate etc.
  • binders e.g. polyvinylpyrrolidone
  • synthetic and natural polymers e.g. albumin
  • stabilizers eg antioxidants such as ascorbic acid
  • dyes eg inorganic pigments such as iron oxides
  • taste and / or smell corrections e.g. microcrystalline cellulose, lactose, mannitol etc.
  • solvents e.g. liquid polyethylene glycols
  • the amount per day is approximately 0.01 to 50 mg / kg, preferably approximately 0.1 to 4 mg / kg body weight.
  • Device type MS Micromass ZQ
  • Device type HPLC Waters Alliance 2795; Column: Merck Chromolith SpeedROD RP-18e 50 mm x 4.6 mm; Eluent A: water + 500 ⁇ l 50% formic acid per 1 water; Eluent B: acetonitrile + 500 ⁇ l 50% formic acid per 1 acetonitrile; Gradient: 0.0 min 10% B ⁇ 3.0 min 95% B ⁇ 4.0 min 95% B; Oven: 35 ° C; Flow: 0.0 min 1.0 ml min ⁇ 3.0 min 3.0 ml / min ⁇ 4.0 min 3.0 ml / min; UV detection: 210 nm.
  • Method 2 Method 2:
  • Device type MS Micromass ZQ
  • Device type HPLC HP 1100 Series
  • UV DAD Column: Grom-Sil 120 ODS-4 HE 50 mm x 2 mm, 3.0 ⁇ m
  • Eluent A water + 500 ⁇ l 50% formic acid per 1 water
  • eluent B acetonitrile + 500 ⁇ l 50% formic acid per 1 acetonitrile
  • Oven 50 ° C
  • Flow 0.8 ml min
  • UV detection 210 nm.
  • Device type MS Micromass ZQ
  • Device type HPLC Waters Alliance 2795; Column: Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20mm x 4mm; Eluent A: 1 1 water + 0.5 ml 50% formic acid, eluent B: 1 1 acetonitrile + 0.5 ml 50% formic acid; Gradient: 0.0 min 90% A, flow 1 ml / min ⁇ 2.5 min 30% A, flow 2 ml min ⁇ 3.0 min 5% A, flow 2 ml / min ⁇ 4.5 min 5% A, flow 2 ml / min; Oven: 50 ° C; UV detection: 210 nm.
  • Device type MS Micromass ZQ
  • Device type HPLC HP 1100 Series
  • UV DAD Column: Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20mm x 4mm
  • Eluent A 1 1 water + 0.5 ml 50% formic acid
  • eluent B 1 1 acetonitrile + 0.5 ml 50% formic acid
  • Gradient: 0.0 min 90% A flow 1 ml / min ⁇ 2.5 min 30% A, flow 2 ml / min ⁇ 3.0 min 5% A, flow 2 ml / min ⁇ 4.5 min 5% A, flow 2 ml / min
  • Oven 50 ° C
  • UV detection 210 nm.
  • the respective reaction mixture is stirred for 2 to 16 hours at room temperature or at temperatures up to 80 ° C and then concentrated in vacuo.
  • the product can be purified by chromatography on silica gel (mobile phase: cyclohexane / ethyl acetate mixtures, dichloromethane / methanol mixtures or dichloromethane / methanol / triethylamine mixtures).
  • reaction mixture is then diluted with dichloromethane and washed with 1 N sodium hydroxide solution.
  • organic phase is dried over magnesium sulfate, filtered and concentrated.
  • residue, which in addition to the desired product also contains triphenylphosphine oxide, is used in the next step without further purification.
  • the title compound is obtained analogously to Example 2 stage a) by reacting 1- (4-aminophenyl) -2-pyrrolidinone with itaconic acid.
  • the title compound is obtained analogously to Example 2 stage c) by reacting methyl 5-oxo-1- [4- (2-oxo-pyrrolidinyl) phenyl] -3-pyrrolidinocarboxylate with sodium borohydride.
  • the title compound is obtained analogously to Example 2 stage d) by reacting 4- (hydroxymethyl) -1- [4- (2-oxo-l-pyrrolidinyl) phenyl] -2-pyrrolidinone with phthalimide.
  • the title compound is analogous to Example 2 stage e) by reacting 2 - ( ⁇ 5-oxo-l- [4- (2-oxo-l-pyrrolidinyl) ⁇ henyl] -3-pyrrolidinyl ⁇ methyl) -lH-isoindole-l , 3 (2H) -dione with ⁇ ydrazine monohydrate.
  • the title compound is obtained analogously to Example 2 stage f) by reacting 4- (aminomethyl) -1- [4- (2-oxo-l-pyrrolidinyl) phenyl] -2-pyrrolidinone with 5-chlorothiophene-2-carboxylic acid chloride.
  • the title compound is prepared according to general method [A] by reacting l- (4-aminophenyl) pyrrolidin-2-one with 5-chloro-N- (2-oxiranylmethyl) -2-thiophenecarboxamide in an ethanol / water mixture ,
  • 2-thiophenecarboxamide [Example 1 step a)] are dissolved in 5 ml DMF and mixed with 56.09 mg (0.3 mmol) N, N'-thiocarbonyldiimidazole and 2.6 mg (0.02 mmol) 4-N, N-dimethylaminopyridine. The solution is stirred at RT for 6 hours and then at 60 ° C. for 12 hours. The The solution is concentrated and the residue is purified by preparative HPLC (column: YMC Gel ODS-AQ S-11 ⁇ m; eluent: water / acetonitrile, gradient 90:10 - »5:95).
  • the solution is stirred at RT for 6 hours and then at 60 ° C. for 12 hours. After concentrating the solution, the residue is dissolved in 10 ml T ⁇ F and mixed with 868 ⁇ l (0.9 mmol) tetra-n-butylammonium fluoride solution (1 M in T ⁇ F). The solution is stirred at RT for 1 hour. After concentrating the solution, the Residue dissolved in ethyl acetate / water (1: 1). After separation, the organic phase is washed with saturated sodium chloride solution, dried and concentrated. The crude product is purified by means of preparative HPLC (column: YMC Gel ODS-AQ S-11 ⁇ m; eluent: water / acetonitrile, gradient 90:10 ⁇ 5:95).
  • the compounds of the formula (I) act in particular as selective inhibitors of the blood coagulation factor Xa and do not inhibit, or only at significantly higher concentrations, other serine proteases such as thrombin, plasmin or trypsin.
  • selective refers to those inhibitors of the blood coagulation factor Xa in which the IC 5 o values for factor Xa inhibition over the IC 5 o values for the inhibition of other serine proteases, in particular thrombin, plasmin and trypsin to the 100- times, preferably 500 times, in particular 1,000 times, are smaller, reference being made with regard to the test methods for the selectivity to the test methods described below for Examples B. al) and a.2).
  • the particularly advantageous biological properties of the compounds according to the invention can be determined by the following methods.
  • the enzymatic activity of human factor Xa was measured via the conversion of a chromogenic substrate specific for the FXa.
  • the factor Xa cleaves p-nitroaniline from the chromogenic substrate. The determinations were carried out in microtiter plates as follows.
  • Pure DMSO serves as a control.
  • the chromogenic substrate 150 ⁇ mol / 1 Pefachrome® FXa from Pentapharm
  • the absorbance at 405 nm was determined.
  • the extinctions of the test mixtures containing test substance were compared with the control mixtures without test substance, and the IC calculates 5 0- values.
  • test substances were examined for their inhibition of other human serine proteases such as thrombin, trypsin, plasmin.
  • thrombin 75 mU / ml
  • trypsin 500 mU / ml
  • plasmin 3.2 nmol 1
  • the enzymatic reaction was then started by adding the corresponding specific chromogenic substrates (Chromozym Thrombin® from Boehringer Mannheim, Chromozym Trypsin® from Boehringer Mannheim, Chromozym Plasmin® from Boehringer Mannheim) and the extinction after 20 minutes at 405 nm certainly. All determinations were carried out at 37 ° C. The extinctions of the test batches with test substance were compared with the control samples without test substance and the IC 50 values were calculated therefrom.
  • the anticoagulant effect of the test substances was determined in vitro in human and rat plasma.
  • human blood was drawn using a 0.11 molar sodium citrate solution as a template in a sodium citrate / blood mixing ratio of 1/9.
  • the blood was mixed well immediately after collection and centrifuged at about 4000 g for 15 minutes. The supernatant was pipetted off.
  • the prothrombin time (PT, synonyms: thromboplastin time, quick test) was determined in the presence of varying concentrations of test substance or the corresponding solvent using a commercially available test kit (Neoplastin® from Boehringer Mannheim or Hemoliance® RecombiPlastin from Instrumentation Laboratory).
  • the test compounds were incubated with the plasma at 37 ° C. for 3 minutes.
  • Fasted male rats (strain: HSD CPB: WU) weighing 200-250 g were anesthetized with a Rompun / Ketavet solution (12 mg / kg / 50 mg / kg). Thrombus formation was carried out in an arteriovenous shunt based on the method described by Christopher N. Berry et al., Br. J. Pharmacol. (1994), 113, 1209-1214 triggered the method described. The left jugular vein and the right carotid artery were dissected. An extracorporeal shunt was placed between the two vessels using a 10 cm long polyethylene tube (PE 60).
  • PE 60 polyethylene tube
  • the middle of this polyethylene tube was bound in a further 3 cm long polyethylene tube (PE 160), which contained a roughened nylon thread and which was put into a loop to produce a thrombogenic surface.
  • PE 160 polyethylene tube
  • the extracorporeal circulation was maintained for 15 minutes.
  • the shunt was then removed and the nylon thread with the thrombus immediately weighed.
  • the empty weight of the nylon thread had been determined before the start of the test.
  • the test substances were administered either intravenously via the tail vein or orally to animals awake using a pharyngeal tube.
  • the compounds according to the invention can be converted into pharmaceutical preparations as follows:
  • Example 1 100 mg of the compound from Example 1, 50 mg lactose, 50 mg microcrystalline cellulose, 10 mg polyvinylpyrrolidone (PVP), 10 mg cross-linked Na carboxymethyl cellulose and 2 mg magnesium stearate.
  • PVP polyvinylpyrrolidone
  • a single dose of 100 mg of the compound according to the invention corresponds to 10 g of oral suspension.
  • the xanthan gum is suspended in ethanol, the active ingredient is added to the suspension.
  • the water is added with stirring.
  • the mixture is stirred for about 6 hours until the swelling of the xanthan gum is complete.
  • a single dose of 100 mg of the compound according to the invention corresponds to 20 g of oral solution.
  • the active ingredient is suspended in the mixture of polyethylene glycol and polysorbate with stirring. The stirring process is continued until the active ingredient has completely dissolved.
  • the active substance is dissolved in a concentration below the saturation solubility in a physiologically acceptable solvent (e.g. isotonic saline, 5% glucose solution, PEG 400 30% solution).
  • a physiologically acceptable solvent e.g. isotonic saline, 5% glucose solution, PEG 400 30% solution.
  • the solution is filtered sterile and filled into sterile and pyrogen-free injection containers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne le domaine de la coagulation du sang. L'invention concerne notamment certains composés hétérocycliques, leur procédé de production, leur utilisation pour traiter et/ou prévenir des maladies ainsi que leur utilisation pour produire des médicaments destinés au traitement et/ou à la prévention de maladies.
EP04731345A 2003-05-19 2004-05-06 Composes heterocycliques Withdrawn EP1626969A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10322469A DE10322469A1 (de) 2003-05-19 2003-05-19 Heterocyclische Verbindungen
PCT/EP2004/004836 WO2004101557A1 (fr) 2003-05-19 2004-05-06 Composes heterocycliques

Publications (1)

Publication Number Publication Date
EP1626969A1 true EP1626969A1 (fr) 2006-02-22

Family

ID=33440957

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04731345A Withdrawn EP1626969A1 (fr) 2003-05-19 2004-05-06 Composes heterocycliques

Country Status (6)

Country Link
US (1) US20070066615A1 (fr)
EP (1) EP1626969A1 (fr)
JP (1) JP4598771B2 (fr)
CA (1) CA2526086A1 (fr)
DE (1) DE10322469A1 (fr)
WO (1) WO2004101557A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AU2003299659A1 (en) 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
EP1571154A1 (fr) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Dérivés du beta-alanine comme inhibiteurs du facteur Xa
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CN1968922A (zh) * 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂
WO2006033948A2 (fr) 2004-09-17 2006-03-30 Durect Corporation Systeme de distribution commandee
EP1724269A1 (fr) * 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Dérivés des amides hétéroarylcarboxyliques-sulfamoylalkylamides comme inhibiteurs du facteur Xa
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
TW200813017A (en) 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2114930A2 (fr) * 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Inhibiteurs du facteur xa
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
CA2706931C (fr) 2007-12-06 2015-05-12 Durect Corporation Formes posologiques pharmaceutiques orales
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2011075602A1 (fr) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Procédés de préparation d'inhibiteurs du facteur xa et de leurs sels
EP2513094B1 (fr) 2009-12-17 2015-12-16 Millennium Pharmaceuticals, Inc. Sels et formes cristallines d'inhibiteur de facteur xa
EP2354128A1 (fr) 2010-02-10 2011-08-10 Sandoz Ag Procédé pour la préparation de rivaroxaban
EP2404920A1 (fr) 2010-07-06 2012-01-11 Sandoz AG Form cristalline de Rivaroxaban dihydrate
AR082804A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
US9221771B2 (en) 2011-04-11 2015-12-29 Sandoz Ag Method for the preparation of substituted oxazolidinones
IN2014DN09450A (fr) 2012-04-16 2015-07-17 Ranbaxy Lab Ltd
EP2855465A1 (fr) 2012-05-24 2015-04-08 Ranbaxy Laboratories Limited Procédé pour la préparation de rivaroxaban
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
WO2015011617A1 (fr) 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Procédé pour la préparation de rivaroxaban
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
AU2017292791B2 (en) 2016-07-06 2023-05-25 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
WO2021146215A1 (fr) 2020-01-13 2021-07-22 Durect Corporation Systèmes d'administration de médicament à libération prolongée avec impuretés réduites et procédés associés
CA3174176A1 (fr) 2020-03-31 2021-10-07 Sanne Schroder Glad Composes actifs vis-a-vis des recepteurs nucleaires
JP7713953B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
DE19504954A1 (de) * 1995-02-15 1996-08-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19755268A1 (de) * 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004101557A1 *

Also Published As

Publication number Publication date
JP4598771B2 (ja) 2010-12-15
CA2526086A1 (fr) 2004-11-25
WO2004101557A1 (fr) 2004-11-25
US20070066615A1 (en) 2007-03-22
DE10322469A1 (de) 2004-12-16
JP2006528943A (ja) 2006-12-28

Similar Documents

Publication Publication Date Title
EP1626969A1 (fr) Composes heterocycliques
EP1366029B1 (fr) 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolines substituees et leur utilisation comme anticoagulants et antithrombotiques
EP1928867B1 (fr) Dérivés d'acide 2-aminoéthoxyacétique et utilisation pour le traitement de maladies thromboemboliques
EP2029546B1 (fr) Hétérocycles substitués par un aryle et leur utilisation
EP2102168A1 (fr) Acylaminopyrazoles destinés au traitement de maladies cardiovasculaires
EP2079708A2 (fr) Acylaminoimidazoles et acylaminothiazoles
EP1414817A1 (fr) Isoindoles substitues et leur utilisation
WO2007140982A1 (fr) Benzoxazole substitué
DE102004058062A1 (de) Cyclische Iminocarbamate und ihre Verwendung
EP2029586B1 (fr) Dérivés d'isoindolin-1-one, d'isoindolin-3-one et d' isoindolin-1,3-dione et leur utilisation
EP1824844B1 (fr) Amides d'acide dicarboxylique de pyrazine et leur utilisation
EP1928868A1 (fr) Derives d'iminooxazolidine et leur utilisation
EP2029582A1 (fr) Dérivés d'isoindolin-1-one, d'isoindolin-3-one et d'isoindolin-1,3-dione et leur utilisation
EP1945634B1 (fr) Derives de phenylene-bis-oxazolidine et leur utilisation en tant qu anticoagulant
EP2032567A1 (fr) Hétérocycles substitués et son utilisation
WO2007082666A1 (fr) Acylaminoimidazoles
WO2006072351A1 (fr) Pyrazolines a substitution heteroaryle en tant qu'antagonistes de par-1
EP1874764B1 (fr) Imino-oxazolidines et leur utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TUCH, AROUNARITH

Inventor name: GERDES, CHRISTOPH

Inventor name: POHLMANN, JENS

Inventor name: SCHLEMMER, KARL-HEINZ

Inventor name: THOMAS, CHRISTIAN, R.

Inventor name: STRAUB, ALEXANDER

Inventor name: PERZBORN, ELISABETH

Inventor name: ROEHRIG, SUSANNE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

RTI1 Title (correction)

Free format text: DERIVATIVES OF OXATHIAZOLIDINE USEFUL FOR THE TREATMENT OF THROMBOEMBOLIC DIESASES AND/OR COMPLICATIONS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111201